Metagenomi Therapeutics Overview
- Year Founded
-
2016
- Status
-
Public
- Employees
-
107
- Stock Symbol
-
MGX
- Share Price
-
$0.69
- (As of Friday Closing)
Metagenomi Therapeutics General Information
Description
Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance its signature gene editing systems. MGX-001 is its, wholly-owned development program in hemophilia A, where the company have demonstrated targeted genome editing and durable gene expression from a one-time treatment in non-human primates (NHPs) and an overall profile potentially competitive with best-in-class treatment options. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A from a single administration.
Contact Information
Website
www.metagenomi.coCorporate Office
- 1545 Park Avenue
- Emeryville, CA 94608
- United States
Corporate Office
- 1545 Park Avenue
- Emeryville, CA 94608
- United States
Metagenomi Therapeutics Stock Performance
As of 13-Nov-2026, Metagenomi Therapeutics’s stock price is $0.69. Its current market cap is $26.2M with 37.8M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.69 | $0.71 | $0.60 - $1.87 | $26.2M | 37.8M | 162K | -$2.50 |
Metagenomi Therapeutics Financials Summary
As of 30-Sep-2026, Metagenomi Therapeutics has a trailing 12-month revenue of $7.09M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | (42,900) | (81,625) | (93,414) | |
| Revenue | 7,086 | 25,210 | 52,295 | 44,756 |
| EBITDA | (94,783) | (92,079) | (92,886) | (71,489) |
| Net Income | (94,195) | (87,868) | (78,058) | (68,255) |
| Total Assets | 157,388 | 221,103 | 324,599 | 364,842 |
| Total Debt | 36,212 | 40,657 | 45,778 | 48,229 |
Metagenomi Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Metagenomi Therapeutics Comparisons
Industry
Financing
Details
Metagenomi Therapeutics Competitors (4)
One of Metagenomi Therapeutics’s 4 competitors is Intellia Therapeutics, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Intellia Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Editas Medicine | Formerly VC-backed | Cambridge, MA | ||||
| Egenesis | Venture Capital-Backed | Cambridge, MA | ||||
| Emendo Biotherapeutics | Formerly VC-backed | Jersey City, NJ |
Metagenomi Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Metagenomi Therapeutics Patents
Metagenomi Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026165476-A1 | Class 2, type v crispr systems | Pending | 03-Feb-2025 | ||
| WO-2026165489-A1 | Compositions and methods for targeting the dystrophin gene | Pending | 03-Feb-2025 | ||
| WO-2026122844-A1 | Class 2, type v crispr systems | Pending | 06-Dec-2024 | ||
| WO-2026122844-A9 | Class 2, type v crispr systems | Pending | 06-Dec-2024 | ||
| WO-2026080408-A1 | Base editing enzymes | Pending | 07-Oct-2024 | C12N15/907 |
Metagenomi Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Metagenomi Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Metagenomi Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Metagenomi Therapeutics FAQs
-
When was Metagenomi Therapeutics founded?
Metagenomi Therapeutics was founded in 2016.
-
Where is Metagenomi Therapeutics headquartered?
Metagenomi Therapeutics is headquartered in Emeryville, CA.
-
What is the size of Metagenomi Therapeutics?
Metagenomi Therapeutics has 107 total employees.
-
What industry is Metagenomi Therapeutics in?
Metagenomi Therapeutics’s primary industry is Drug Discovery.
-
Is Metagenomi Therapeutics a private or public company?
Metagenomi Therapeutics is a Public company.
-
What is Metagenomi Therapeutics’s stock symbol?
The ticker symbol for Metagenomi Therapeutics is MGX.
-
What is the current stock price of Metagenomi Therapeutics?
As of 13-Nov-2026 the stock price of Metagenomi Therapeutics is $0.69.
-
What is the current market cap of Metagenomi Therapeutics?
The current market capitalization of Metagenomi Therapeutics is $26.2M.
-
What is Metagenomi Therapeutics’s current revenue?
The trailing twelve month revenue for Metagenomi Therapeutics is $7.09M.
-
Who are Metagenomi Therapeutics’s competitors?
Intellia Therapeutics, Editas Medicine, Egenesis, and Emendo Biotherapeutics are competitors of Metagenomi Therapeutics.
-
What is Metagenomi Therapeutics’s annual earnings per share (EPS)?
Metagenomi Therapeutics’s EPS for 12 months was -$2.50.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
